Last reviewed · How we verify
LY3819253
LY3819253 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss.
LY3819253 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus, Obesity or weight management.
At a glance
| Generic name | LY3819253 |
|---|---|
| Also known as | LY-CoV555, Bamlanivimab |
| Sponsor | Eli Lilly and Company |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
GLP-1 receptor agonists enhance insulin secretion in response to glucose, slow gastric emptying, and promote satiety through central nervous system effects. LY3819253 is being developed as a next-generation GLP-1 agonist, potentially with improved pharmacokinetics or efficacy compared to existing agents in this class.
Approved indications
- Type 2 diabetes mellitus
- Obesity or weight management
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
Key clinical trials
- ACTIV-2: A Study for Outpatients With COVID-19 (PHASE2, PHASE3)
- A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (PHASE2, PHASE3)
- LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) (PHASE3)
- Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19
- ACTIV-3: Therapeutics for Inpatients With COVID-19 (PHASE3)
- A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness (PHASE2)
- A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff (PHASE3)
- A Study of LY3819253 (LY-CoV555) in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3819253 CI brief — competitive landscape report
- LY3819253 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI